drugset / Trial / NCT00667589

Sorafenib-induced Hand- Foot Skin Reaction Treatment

NCT00667589

Phase 2 Terminated 6 enrolled Northwestern University Bayer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate treatments for a rash caused by sorafenib.

Timeline

Start
2008-06
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluocinonide Other / unclassified 0.05 % Topical
Subject Tazarotene Small molecule 0.1 % Topical
Subject Udderly smooth® Udder Cream Unknown Topical
Subject urea Unknown 40 % Topical